Endothelium-derived nitric oxide (NO) is the most potent endogenous vasodilator and, by virtue of its anti-inflammatory and anti-thrombotic effects, it is an endogenous anti-atherogenic agent. Accordingly, impairment of NO synthesis or bioactivity may increase the risk of vascular disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of the NO synthase pathway. Plasma levels of ADMA are increased in patients with vascular disease, or with risk factors for vascu lar disease. Preclinical and clinical studies indicate that ADMA may mediate the adverse effects of traditional risk factors on endothelial vasodilator function. By impairing endothelial function, ADMA may contribute to pulmonary or systemic hypertension, as well as to vascular disease. Several drugs known to treat cardiovas cular disease also reduce plasma ADMA levels, such as angiotensin receptor antag onists, converting enzyme inhibitors, and insulin sensitizing agents. Plasma ADMA may be a common mediator of endothelial dysfunction induced by vascular risk factors. Insights into the mechanisms by which plasma ADMA is regulated may lead to new therapeutic knowledge.
Cooke JP, Rossitch E., Andon N., Loscalzo J., Dzau VJFlow activates an endothelial potassium channel to release an endogenous nitrovasodilator . J Clin Invest1991; 88: 1663-71.
2.
Davies PFMultiple signaling pathways in flow-mediated endothelial mechanotransduction: PYK-ing the right location. Arterioscler Thromb Vasc Biol2002; 22: 1755-57.
3.
Cocks TM, Angus JAEndothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature1983; 305: 627-30.
4.
Vanhoutte PM , Rubanyi GM, Miller VM, Houston DSAdenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol1985 ; 248(3 Pt 2): H389-95.
5.
Warner TD, Mitchell JA, de Nucci G., Vane JREndothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol1989; 13 Suppl 5: S85-88.
6.
Hirsch AT, Dzau VJ, Majzoub JA, Creager MAVasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. J Clin Invest1989; 84: 418-26.
7.
Tsao PS, Buitrago R., Chan JR, Cooke JPFluid flow inhibits endothelial adhesiveness: nitric oxide and transcriptional regulation of VCAM-1. Circulation1996; 94: 1682-89.
8.
Tsao PS, Wang B., Buitrago R., Shyy JY, Cooke JPNitric oxide regulates monocyte chemotactic protein-1. Circulation1997; 96: 934-40.
9.
Stamler JS, Mendelsohn ME, Amarante P. et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res1989; 65:789-95.
10.
Oelze M., Mollnau H., Hoffmann N. et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res2000; 87: 999-1005.
11.
Garg UC, Hassid A.Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest1989; 83: 1774-77.
12.
Bauer PM, Buga GM, Ignarro LJRole of p42/p44 mitogenactivated-protein kinase and p21waf1/cip in the regulation of vascular smooth muscle cell proliferation by nitric oxide . Proc Natl Acad Sci U S A 2001; 98: 12802-807.
13.
Dimmeler S. , Hermann C., Galle J., Zeiher AMUpregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. Arterioscler Thromb Vasc Biol1999; 19: 656-64.
14.
Wang BY, Ho HK, Lin PS et al. Regression of atherosclerosis: role of nitric oxide and apoptosis . Circulation1999; 99: 1236-41.
15.
Krumenacker JS, Hanafy KA, Murad F.Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull2004; 62: 505-15.
16.
Singel DJ, Stamler JSChemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin [Review]. Annu Rev Physiol2005; 67: 99-145.
17.
Ohara Y., Petersen TE, Harrison DGHypercholesterolemia increases endothelial superoxide anion production . J Clin Invest1993; 91: 2546-51.
18.
Rubanyi GM, Vanhoutte PMSuperoxide anions and hyperoxia inactivate endothelium-derived relaxing factor . Am J Physiol.1986; 250(5 Pt 2): H822-27.
19.
Beckman JS, Koppenol WHNitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly . Am J Physiol1996; 271: C1424-37.
20.
Mügge A., Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DGChronic treatment with polyethyleneglycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits . Circ Res1991; 69: 1293-300.
21.
Gokce N., Keaney JF Jr, Frei B. et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation1999; 99: 3234-40.
22.
Ramasamy S. , Drummond GR, Ahn J. et al. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Mol Pharmacol1999; 56: 116-23.
23.
Pou S., Pou WS, Bredt DS, Snyder SH, Rosen GMGeneration of superoxide by purified brain nitric oxide synthase. J Biol Chem1992; 267: 24173-76.
24.
Stroes E., Kastelein J., Cosentino F. et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia . J Clin Invest1997; 99: 41-46.
25.
Xia Y., Tsai AL, Berka V., Zweier JLSuperoxide generation from endothelial nitric-oxide synthase. A Ca2 +/calmodulindependent and tetrahydrobiopterin regulatory process. J Biol Chem1998; 273: 25804-808.
26.
Pritchard KA , Groszek L., Smalley DM et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide. AnionCirc Res1995; 77: 510-18.
27.
Vasquez-Vivar J., Kalyanaraman B., Martasek P. et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A1998; 95: 9220-25.
28.
Huang A., Vita JA, Venema RC, Keaney J.Ascorbic acid enhances endothelial nitric oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem2000; 275: 17399-406.
29.
Oemar BS, Tschudi MR, Godoy N., Brovkovich V., Malinski T., Luscher TFReduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation1998 ; 97: 2494-98.
30.
Liao JK, Shin WS, Lee WY, Clark SLOxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem1995; 270: 319-24.
31.
Hingorani AD , Liang CF, Fatibene J. et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation1999 ; 100: 1515-20.
32.
Vallance P. , Leone A., Calver A., Collier J., Moncada S.Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure . Lancet1992; 339: 572-75.
33.
Miyazaki H. , Matsuoka H., Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation1999; 99: 1141-46.
34.
Surdacki A. , Nowicki M., Sandmann J. et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol1999; 33: 652-58.
35.
Fujiwara N. , Osanai T., Kamada T., Katoh T., Takahashi K., Okumura K.Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake . Circulation2000; 101: 856-61.
36.
Abbasi F., Asagmi T., Cooke JP et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol2001; 88: 1201-203.
37.
Stuhlinger MC, Abbasi F., Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor . JAMA2002; 287: 1420-26.
38.
Böger RH, Bode-Böger SM, Szuba A. et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation1998;98:1842-47.
39.
Lundman P., Eriksson MJ, Stuhlinger M., Cooke JP, Hamsten A., Tornvall P.Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine . J Am Coll Cardiol2001; 38: 111-16.
40.
Stuhlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of ADMA. Circulation2003; 108: 933-38.
41.
Fard A., Tuck CH, Donis JA et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol2000; 20: 2039-44.
42.
Zoccali C., Benedetto FA, Maas R. et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol2002; 13: 490-96.
43.
Beppu M., Obayashi S., Aso T. et al. Endogenous nitric oxide synthase inhibitors in endothelial cells, endothelin-1 within the vessel wall, and intimal hyperplasia in perimenopausal human uterine arteries. J Cardiovasc Pharmacol2002; 39: 192-200.
44.
Yoo JH, Lee SCElevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis2001; 158: 425-30.
45.
Usui M., Matsuoka H., Miyazaki H. et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci1998 ; 62: 2425-30.
46.
Böer RH, Bode-Böger SM, Thiele W. et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation1997; 95: 2068-74.
47.
Böger RH, Bode-Böger SM, Thiele W. et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol1998; 32: 1336-44.
48.
Selley MLIncreased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging2003; 24: 903-907.
49.
Nijveldt RJ , Teerlink T., van der Hoven B. et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr2003 ; 22: 23-30.
50.
Valkonen VP , Paiva H., Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet2001; 358: 2127-28.
51.
Zoccali C., Bode-Böger S., Mallamaci F. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet2001; 358: 2113-17.
52.
Ito A., Tsao PS, Adimoolam S., Kimoto M., Ogawa T., Cooke JPNovel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation1999; 99: 3092-95.
53.
Stuhlinger MC, Tsao PS, Her J-H., Kimoto M., Balint RF, Cooke JP: Homocysteine impairs the NO synthase pathway- role of asymmetric dimethylarginine. Circulation2001; 104: 2569-75.
54.
Lin KY, Ito A., Asagami T. et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase . Circulation2002; 106: 987-92.
55.
Weis M., Kledal TN, Lin KY et al. Cytomegalovirus infection impairs the NOS pathway. Role of ADMA in transplant arteriosclerosis. Circulation2004; 109: 500-505.
56.
Leiper J., Murray-Rust J., McDonald N. et al. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A2002; 99: 13527-32.
57.
Dayoub H., Achan V., Adimoolam S. et al. DDAH regulates NO synthesis: genetic and physiological evidence . Circulation2003; 108: 1043-48.
58.
Jang J., Ho H-K., Kwan HH, Adimoolam S., Fajardo LF, Cooke JPAngiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine . Circulation2000; 102: 1414-19.
59.
Cooke JPNO and angiogenesis. Atheroscler Suppl2003 ; 4:53-60.
60.
Jacobi J., Sydow K., von Degenfeld G. et al. Regulation of angiogenesis by DDAH. Circulation (in press).
61.
Hayry P., Isoniemi H., Yilmaz S. et al. Chronic allograft rejection. Immunol Rev1993; 134: 33-81.
62.
Weis M., von Scheidt W.Coronary artery disease in the transplanted heart. Annu Rev Med2000; 51: 81-100.
63.
Gaudin PB, Rayburn BK, Hutchins GM et al. Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients . Am J Surg Pathol1994; 18: 338-46.
Taylor DO, Edwards LB, Mohacsi PJ et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report - 2003. J Heart Lung Transplant2003; 22: 616-24.
66.
Valantine HACardiac allograft vasculopathy: central role of endothelial injury leading to transplant 'atheroma'. Transplantation2003; 76: 891-99.
67.
Tanaka M., Sydow K., Gunawan F. et al. DDAH overexpression suppresses graft coronary artery disease in murine cardiac allografts. Circulation2005 (in press).
